Prevention of thromboembolic complications in patients with end-stage kidney disease and atrial fibrillation
Sh.S. Abdullaev, R.Sh. Igamberdieva
1) Tashkent Pediatric Medical Institute, Tashkent, Uzbekistan;
2) Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation, Tashkent, Uzbekistan
End-stage kidney disease has a high risk of thromboembolic complications, which is further exacerbated by the addition of atrial fibrillation. The comorbidity of these pathologies presents a unique problem due to the combination of increased risk of stroke and bleeding. When prescribing anticoagulants, treatment adherence and persistence are low, thus, many patients are not receiving treatment. Newer oral anticoagulants may offer an alternative to a vitamin K antagonist in patients with end-stage kidney disease, but these drugs have not been extensively studied in this population, and therefore, uncertainty about comparative efficacy remains. In this review, we discuss current data on the risks and benefits of anticoagulants in this challenging setting.
About the Autors
Sherzod S. Abdullaev – Dr. Sci. (Med.), Associate Professor at the Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent Pediatric Medical Institute; Head of the Department of Immunogenetics, Republican Specialized Scientific and Practical Medical Center for Nephrology and Kidney Transplantation, Tashkent, Uzbekistan; e-mail: firstname.lastname@example.org.
Ranokhon Sh. Igamberdieva – Teaching Assistant at the Department of Internal Medicine, Nephrology and Hemodialysis, Tashkent Pediatric Medical Institute; Tashkent, Uzbekistan; e-mail: email@example.com.